Please assess the completion status of the following clinical trial:

Trial Title: An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult men and women aged 19 years or more~2. Patients with cancerous pain who are hospitalized or scheduled for hospitalization at Screening and not planned to be discharged during the study~3. Patients with mean moderate to severe pain over the past 7 days at Screening as verbally confirmed (NRS 4 or higher)~4. Subjects who voluntarily signed the Informed Consent Form for the study~5. Subjects who are capable of understanding details of the study and verbal communication on pain intensity~Exclusion Criteria:~1. Patients who reached the narcotic analgesic dose corresponding to the followings for cancerous pain treatment immediately prior to Screening (oral morphine dose 195mg/day, oral oxycodone dose 130mg/day, patch fentanyl dose 75μg/hour)~2. Patients with a medical history of hypersensitivity to an ingredient of oxycodone hydrochloride or morphine sulfate or other narcotic analgesics~3. Patients who have contraindications and cautions when study drugs administered.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxycodone Hydrochloride (Type: EXPERIMENTAL): Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride
- Morphine Sulphate (Type: ACTIVE_COMPARATOR): Brand name: BC Morphine sulfate Generic name: Morphine sulfate

Based on this trial design, predict the completion outcome and termination type (if applicable).